PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Clinical Trials
5.0k
Trial Phases
6 Phases
Drug Approvals
69
Drug Approvals
Rimegepant Sulfate Orally Disintegrating Tablets
- Product Name
- 乐泰可
- Approval Number
- 国药准字HJ20240004
- Approval Date
- Jan 23, 2024
Ritlecitinib Tosylate Capsules
- Product Name
- 乐复诺
- Approval Number
- 国药准字HJ20230118
- Approval Date
- Oct 18, 2023
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (3925 trials with phase data)• Click on a phase to view related trials
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Advanced Non-Small Cell Lung CancerNon-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungCarcinoma, Non-Small-Cell Lung (NSCLC)Metastatic Non Small Cell Lung CancerLung Cancer
- Interventions
- Biological: PF-08634404Drug: Chemotherapy Regimen 1Drug: Chemotherapy Regimen 2
- First Posted Date
- 2025-10-30
- Last Posted Date
- 2025-10-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1500
- Registration Number
- NCT07222566
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Conditions
- Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal DiseasesColorectal Neoplasms
- Interventions
- First Posted Date
- 2025-10-30
- Last Posted Date
- 2025-10-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 800
- Registration Number
- NCT07222800
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- First Posted Date
- 2025-10-22
- Last Posted Date
- 2025-10-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 200
- Registration Number
- NCT07219615
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
- Conditions
- Atopic DermatitisEczema, Atopic
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-10-14
- Last Posted Date
- 2025-10-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 200
- Registration Number
- NCT07216027
Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants
- Conditions
- Healthy Volunteer
- Interventions
- Drug: atirmociclib (PF-07220060)
- First Posted Date
- 2025-10-10
- Last Posted Date
- 2025-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 72
- Registration Number
- NCT07215078
- Locations
- 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 641
- Next
News
FDA Proposes Streamlined Biosimilar Approval Process to Reduce Drug Costs by 50%
The FDA announced new draft guidance to simplify biosimilar approval by reducing clinical testing requirements and shortening development timelines.
FDA Proposes Streamlined Approval Pathway to Accelerate Biosimilar Drug Development
The U.S. FDA released draft guidance proposing to reduce human clinical study requirements for certain biosimilar drugs and treat them more like generic medications to accelerate market availability.
BioMarin to Divest Roctavian Gene Therapy Following Commercial Struggles
BioMarin Pharmaceutical announced plans to divest Roctavian, its hemophilia A gene therapy, after the treatment generated only $26 million in sales in 2024 versus initial projections of $100-200 million.
AstraZeneca Establishes Sixth Global R&D Center in Beijing to Accelerate AI-Driven Drug Discovery
AstraZeneca officially opened its sixth global strategic R&D center in Beijing's BioPark, marking the company's second facility in China alongside its Shanghai center.
Flagship Pioneering Launches Expedition Medicines with $50M Investment in AI-Driven Covalent Drug Discovery
Flagship Pioneering has launched Expedition Medicines with a $50 million investment, focusing on AI-driven drug discovery for cancer and immune diseases using covalent chemistry principles.
Pfizer's BRAFTOVI Plus MEKTOVI Achieves Nearly Four-Year Survival in BRAF-Mutant Lung Cancer
Pfizer's BRAFTOVI plus MEKTOVI combination therapy demonstrated a median overall survival of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer.
Dovato Demonstrates Non-Inferior Efficacy to Biktarvy with Significantly Less Weight Gain in 96-Week HIV Treatment Study
ViiV Healthcare's PASO DOBLE trial shows Dovato (DTG/3TC) maintains viral suppression as effectively as Biktarvy (BIC/FTC/TAF) at 96 weeks in 553 virologically suppressed HIV-1 patients.
Activist Investor Shah Capital Calls for Novavax Sale Amid COVID Vaccine Market Share Struggles
Shah Capital, Novavax's second-largest shareholder with a 7.2% stake, has urged the company's board to pursue a sale, citing three consecutive years of poor COVID-19 vaccine performance.
Dublin Biotech Meta-Flux Raises €1.8M to Enhance Drug Development Accuracy with AI Platform
Dublin-based biotech Meta-Flux has secured €1.8 million in seed funding from senior executives at Pfizer, Merck, and Gilead Sciences to expand its AI-powered drug development platform.
Eli Lilly and AstraZeneca Emerge as Leading Candidates for Next Trump Administration Drug Pricing Deal
Wall Street analysts predict Eli Lilly and AstraZeneca are the most likely pharmaceutical companies to strike the next drug pricing deal with the Trump administration following Pfizer's September 29 agreement.